Bioscience

PBS-Bio works with 3 new firms to accelerate cancer drug development

October 20, 2010

By Flinn Foundation

[Source: TGen] – In an industry that faces increasing challenges in delivering new drugs to patients, Predictive Biomarker Sciences (PBS-Bio) today announced three new contracts aimed at bringing new medicines to the marketplace.

PBS-Bio said it is helping more companies develop therapies against a variety of cancers. Most new cancer drugs fail in late-stage studies, and it can take as much as $1 billion and more than a decade to bring the drugs to market.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

For more information: PBS-Bio works with 3 new firms to accelerate cancer drug development